PCA
GLUE icon

Pallas Capital Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Pallas Capital Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Buy
+9,138
New +$173K 0.01% 863
2026
Q1 		– Sell
-11,320
Closed -$177K – 911
2025
Q4 		$177K Buy
11,320
+126
+1% +$1.7K 0.01% 822
2025
Q3 		$82.9K Sell
11,194
-1,988
-15% -$10.5K ﹤0.01% 835
2025
Q2 		$59.5K Buy
+13,182
New +$58.8K ﹤0.01% 817

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pallas Capital Advisors's GLUE Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 9,138 shares worth $221K. The stake represents 0.01% of the portfolio and ranks #863 among its holdings. This is a return to the name: Pallas Capital Advisors previously reported a position in GLUE as recently as Q4 2025.

Pallas Capital Advisors first reported a position in GLUE in Q2 2025 and has held it in 4 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Pallas Capital Advisors held 9,138 shares of Monte Rosa Therapeutics worth $221K as of Q2 2026.
  • Monte Rosa Therapeutics was a new Pallas Capital Advisors position in Q2 2026.
  • Monte Rosa Therapeutics made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #863 holding.
  • Pallas Capital Advisors first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.